Recro Pharma, Inc. (REPH) financial statements (2021 and earlier)
Company profile
Business Address |
490 LAPP ROAD MALVERN, PA 19355 |
State of Incorp. | PA |
Fiscal Year End | December 31 |
SIC | 2834 - Pharmaceutical Preparations (benchmarking) |
More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in millions)
12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | |||
---|---|---|---|---|---|---|---|---|
ASSETS | ||||||||
Current Assets | ||||||||
Cash, cash equivalents, and short-term investments | 19 | 39 | 64 | 64 | 20 | 20 | ||
Cash and cash equivalents | 19 | 39 | 61 | 64 | 20 | 20 | ||
Short-term investments | 3 | |||||||
Receivables | 14 | 13 | 10 | 10 | 9 | 0 | ||
Inventory, net of allowances, customer advances and progress billings | 15 | 11 | 10 | 9 | 9 | |||
Inventory | 15 | 11 | 10 | 9 | 9 | |||
Prepaid expense | 1 | 1 | ||||||
Contract with customer, asset | 9 | 5 | ✕ | ✕ | ✕ | ✕ | ||
Deferred costs | 1 | |||||||
Other undisclosed current assets | 3 | 4 | 3 | 1 | ||||
Total current assets: | 60 | 71 | 87 | 85 | 39 | 20 | ||
Noncurrent Assets | ||||||||
Operating lease, right-of-use asset | 0 | ✕ | ✕ | ✕ | ✕ | ✕ | ||
Property, plant and equipment | 42 | 46 | 39 | 37 | 38 | |||
Intangible assets, net (including goodwill) | 8 | 39 | 41 | 44 | 46 | |||
Goodwill | 4 | 6 | 6 | 6 | 6 | |||
Intangible assets, net (excluding goodwill) | 3 | 32 | 35 | 37 | 40 | |||
Deferred costs | 3 | |||||||
Deferred tax assets, net | ✕ | 19 | 17 | 16 | ||||
Other undisclosed noncurrent assets | (3) | |||||||
Total noncurrent assets: | 50 | 84 | 99 | 98 | 100 | |||
TOTAL ASSETS: | 110 | 155 | 186 | 183 | 139 | 20 | ||
LIABILITIES AND EQUITY | ||||||||
Liabilities | ||||||||
Current Liabilities | ||||||||
Accounts payable and accrued liabilities | 5 | 19 | 18 | 14 | 5 | 1 | ||
Accounts payable | 1 | 5 | 8 | 4 | 2 | 1 | ||
Accrued liabilities | 4 | 14 | 10 | 10 | 3 | 1 | ||
Employee-related liabilities | 0 | |||||||
Debt | 0 | 2 | 5 | |||||
Disposal group, including discontinued operation | 1 | |||||||
Business combination, contingent consideration, liability | 10 | 32 | ||||||
Other undisclosed current liabilities | (0) | |||||||
Total current liabilities: | 6 | 29 | 50 | 16 | 9 | 1 | ||
Noncurrent Liabilities | ||||||||
Long-term debt and lease obligation | 111 | 64 | 54 | 22 | 25 | |||
Long-term debt, excluding current maturities | 110 | 64 | 54 | 22 | 25 | |||
Operating lease, liability | 0 | ✕ | ✕ | ✕ | ✕ | ✕ | ||
Liabilities, other than long-term debt | 81 | 50 | ||||||
Business combination, contingent consideration, liability | 81 | 50 | ||||||
Other undisclosed noncurrent liabilities | 1 | 4 | 73 | 64 | ||||
Total noncurrent liabilities: | 111 | 146 | 107 | 95 | 89 | |||
Total liabilities: | 117 | 175 | 157 | 111 | 98 | 1 | ||
Stockholders' equity | ||||||||
Stockholders' equity attributable to parent | (7) | (20) | 29 | 72 | 40 | 19 | ||
Common stock | 0 | 0 | 0 | 0 | 0 | 0 | ||
Additional paid in capital | 200 | 169 | 140 | 133 | 71 | 53 | ||
Accumulated other comprehensive loss | (0) | |||||||
Accumulated deficit | (207) | (188) | (111) | (61) | (31) | (34) | ||
Total stockholders' equity: | (7) | (20) | 29 | 72 | 40 | 19 | ||
TOTAL LIABILITIES AND EQUITY: | 110 | 155 | 186 | 183 | 139 | 20 |
Income statement (P&L) ($ in millions)
12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | ||
---|---|---|---|---|---|---|---|
Revenues | 99 | 77 | 72 | 69 | 52 | ||
Cost of revenue | (53) | (47) | (46) | (42) | (32) | ||
Cost of goods and services sold | (51) | (43) | (38) | (37) | (28) | ||
Gross profit: | 46 | 31 | 26 | 28 | 20 | ||
Operating expenses | (22) | (85) | (66) | (54) | (27) | (12) | |
Operating income (loss): | 24 | (54) | (40) | (26) | (7) | (12) | |
Nonoperating income (expense) | 1 | 0 | 0 | 0 | (4) | ||
Investment income, nonoperating | 1 | 0 | 0 | 0 | 0 | ||
Interest and debt expense | (20) | (9) | (12) | (6) | (6) | (4) | |
Income (loss) from continuing operations before equity method investments, income taxes: | 4 | (62) | (52) | (31) | (13) | (20) | |
Other undisclosed income from continuing operations before income taxes | 20 | ||||||
Income (loss) from continuing operations before income taxes: | 24 | (62) | (52) | (31) | (13) | (20) | |
Income tax expense (benefit) | (1) | (17) | 2 | 1 | 16 | ||
Income (loss) from continuing operations: | 23 | (80) | (50) | (30) | 3 | (20) | |
Loss from discontinued operations | (23) | ||||||
Income (loss) before gain (loss) on sale of properties: | (1) | (80) | (50) | (30) | 3 | (20) | |
Other undisclosed net loss | (18) | ||||||
Net income (loss): | (19) | (80) | (50) | (30) | 3 | (20) | |
Other undisclosed net income attributable to parent | 4 | ||||||
Net income (loss) attributable to parent: | (19) | (80) | (50) | (30) | 3 | (16) | |
Preferred stock dividends and other adjustments | (1) | ||||||
Net income (loss) available to common stockholders, basic: | (19) | (80) | (50) | (30) | 3 | (17) | |
Dilutive securities, effect on basic earnings per share | (1) | ||||||
Net income (loss) available to common stockholders, diluted: | (19) | (80) | (50) | (30) | 2 | (17) |
Comprehensive Income ($ in millions)
12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | ||
---|---|---|---|---|---|---|---|
Net income (loss): | (19) | (80) | (50) | (30) | 3 | (20) | |
Other comprehensive income (loss) | 0 | (0) | |||||
Comprehensive income (loss), net of tax, attributable to parent: | (19) | (80) | (50) | (30) | 3 | (20) |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.